Clinical Trials for Head & Neck Cancer

XL092-305

A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. View details.


Learn more about Head and Neck Cancer >

Our Affiliations

The Cancer FoundationNCIACHC Accredited

We’re Here to Help! Click Below to Get Started

Contact Us Now